70 related articles for article (PubMed ID: 33664522)
1. Maintaining 'standards' for biosimilar monoclonal antibodies.
Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
[No Abstract] [Full Text] [Related]
2. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
Heinemann L; Khatami H; McKinnon R; Home P
Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
[TBL] [Abstract][Full Text] [Related]
3. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.
Reichert JM
MAbs; 2011; 3(3):223-40. PubMed ID: 21487235
[TBL] [Abstract][Full Text] [Related]
4. New Biosimilar Drugs Approved for Osteoporosis.
Aschenbrenner DS
Am J Nurs; 2024 Jul; 124(7):16. PubMed ID: 38900119
[No Abstract] [Full Text] [Related]
5. Maximizing the success of biosimilar implementation.
Alten R; Weinbrecht-Mischkewitz M
Nat Rev Rheumatol; 2023 Dec; 19(12):757-758. PubMed ID: 37903917
[No Abstract] [Full Text] [Related]
6. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A; Furtner D; Melsheimer R; Molloy PJ
Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
Tanaka E; Kawahito Y; Kohno M; Hirata S; Kishimoto M; Kaneko Y; Tamai H; Seto Y; Morinobu A; Sugihara T; Murashima A; Kojima M; Mori M; Ito H; Kojima T; Sobue Y; Nishida K; Matsushita I; Nakayama T; Yamanaka H; Harigai M
Mod Rheumatol; 2022 Jan; 32(1):74-86. PubMed ID: 33706664
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma.
Kumar G; DSouza H; Menon N; Srinivas S; Vallathol DH; Boppana M; Rajpurohit A; Mahajan A; Janu A; Chatterjee A; Krishnatry R; Gupta T; Jalali R; Patil VM
Ecancermedicalscience; 2021; 15():1166. PubMed ID: 33680080
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Actions of 25-Hydroxycholesterol in Fish Vary With the Virus-Host Combination.
Adamek M; Davies J; Beck A; Jordan L; Becker AM; Mojzesz M; Rakus K; Rumiac T; Collet B; Brogden G; Way K; Bergmann SM; Zou J; Steinhagen D
Front Immunol; 2021; 12():581786. PubMed ID: 33717065
[TBL] [Abstract][Full Text] [Related]
10. BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines.
Foster M; Hill PC; Setiabudiawan TP; Koeken VACM; Alisjahbana B; van Crevel R
Immunol Rev; 2021 May; 301(1):122-144. PubMed ID: 33709421
[TBL] [Abstract][Full Text] [Related]
11. Active equine parvovirus-hepatitis infection is most frequently detected in Austrian horses of advanced age.
Badenhorst M; de Heus P; Auer A; Tegtmeyer B; Stang A; Dimmel K; Tichy A; Kubacki J; Bachofen C; Steinmann E; Cavalleri JMV
Equine Vet J; 2022 Mar; 54(2):379-389. PubMed ID: 33704819
[TBL] [Abstract][Full Text] [Related]
12. Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection.
Behrendt P; Bremer B; Todt D; Steinmann E; Manns MP; Cornberg M; Wedemeyer H; Maasoumy B
Liver Int; 2021 Aug; 41(8):1815-1823. PubMed ID: 33683813
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
14. Heparan Sulfate Is a Cellular Receptor for Enteric Human Adenoviruses.
Rajan A; Palm E; Trulsson F; Mundigl S; Becker M; Persson BD; Frängsmyr L; Lenman A
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672966
[TBL] [Abstract][Full Text] [Related]
15. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.
Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Gardarsdottir H
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33669108
[TBL] [Abstract][Full Text] [Related]
16. Quantification of SARS-CoV-2 monoclonal IgG mass fraction by isotope dilution mass spectrometry.
Martos G; Bedu M; Josephs RD; Westwood S; Wielgosz RI
Anal Bioanal Chem; 2024 Apr; 416(10):2423-2437. PubMed ID: 38427100
[TBL] [Abstract][Full Text] [Related]
17. WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June - 2 July 2021.
Wadhwa M; Kang HN; Thorpe R; Knezevic I; ; Aprea P; Bielsky MC; Ekman N; Heim HK; Joung J; Kurki P; Lacana E; Njue C; Nkansah E; Savkina M; Thorpe R; Yamaguchi T; Wadhwa M; Wang J; Weise M; Wolff-Holz E; ; ; ; ; ; ; ;
Biologicals; 2022 Apr; 76():1-9. PubMed ID: 35466023
[TBL] [Abstract][Full Text] [Related]
18. The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab.
Jia H; Harikumar P; Atkinson E; Rigsby P; Wadhwa M
Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827607
[TBL] [Abstract][Full Text] [Related]
19. New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment.
Oliva A; Llabrés M
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34205892
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19.
Patel S; Wadhwa M
Biomed Pharmacother; 2021 Aug; 140():111785. PubMed ID: 34126316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
